Trial NCT01751425

View at ClinicalTrials.gov 
Org. Study IDs: 2012-0697
Secondary IDs: 2012-0697 NCI-2018-01797 P30CA016672

Last trial update was posted on 2023-12-05

MeSH Interventions

Dasatinib Imatinib Mesylate Janus Kinase Inhibitors Nilotinib

MeSH Conditions

Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid Neoplasm, Residual Philadelphia Chromosome

Other Conditions

Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission Minimal Residual Disease Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

Stopping Reasons

Per PI Request. 2) No additional benefit was noted with the addition of Ruxolitinib.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID